Biochemical analysis demonstrates how histone acetylation enhances SETD2's tumor suppressor role, suggesting a vital connection to cancer pathogenesis.
Key Points
SETD2 functions as a significant tumor suppressor in KRAS G12C-driven lung cancer.
Acetylation enhances SETD2's ability to methylate histone H3K36 in tumor models.
Setd2 loss accelerates tumor progression and lethality in lung adenocarcinoma mouse models.
The study highlights the importance of histone modifications in regulating tumor suppression and cancer development.